1-5 of 5
Judit Matito
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma During Targeted Therapy

Alberto González-Medina, Maria Vila-Casadesús, Marina Gomez-Rey, Carles Fabregat-Franco, Alexandre Sierra, Tian V. Tian, Florian Castet, Gloria Castillo, Judit Matito, Paola Martinez, Josep M. Miquel, Paolo Nuciforo, Raquel Pérez-López, Teresa Macarulla, Ana Vivancos
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (19): 4491–4504.
https://doi.org/10.1158/1078-0432.CCR-23-3780
Published: 01 October 2024
View article titled, Clinical Value of Liquid Biopsy in Patients with <em>FGFR2</em> Fusion–Positive Cholangiocarcinoma During Targeted Therapy
Open the PDF for Clinical Value of Liquid Biopsy in Patients with <em>FGFR2</em> Fusion–Positive Cholangiocarcinoma During Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cristina Saura, Judit Matito, Mafalda Oliveira, Hans Wildiers, Adam M. Brufksy, Simon H. Waters, Sara A. Hurvitz, Beverly Moy, Sung-Bae Kim, William J. Gradishar, Geraldo Silva Queiroz, Eduardo Cronemberger, Gerald J. Wallweber, Judith Bebchuk, Kiana Keyvanjah, Alshad S. Lalani, Richard Bryce, Ana Vivancos, Lisa D. Eli, Suzette Delaloge
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (21): 5818–5827.
https://doi.org/10.1158/1078-0432.CCR-21-1584
Published: 01 November 2021
View article titled, Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
Open the PDF for Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jimenez-Fonseca, Carlos Lopez Lopez, Rocio Garcia-Carbonero, Jorge Hernando, Ignacio Matos, Nuciforo Paolo, Javier Hernández-Losa, Manel Esteller, Anna Martínez-Cardús, Josep Tabernero, Ana Vivancos, Héctor G. Palmer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (4): 902–909.
https://doi.org/10.1158/1078-0432.CCR-19-1266
Published: 14 February 2020
View article titled, Epigenetic <em>EGFR</em> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Open the PDF for Epigenetic <em>EGFR</em> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas in another window
Includes: Supplementary data
Journal Articles

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Oriol Arqués, Irene Chicote, Isabel Puig, Stephan P. Tenbaum, Guillem Argilés, Rodrigo Dienstmann, Natalia Fernández, Ginevra Caratù, Judit Matito, Daniel Silberschmidt, Jordi Rodon, Stefania Landolfi, Aleix Prat, Eloy Espín, Ramón Charco, Paolo Nuciforo, Ana Vivancos, Wenlin Shao, Josep Tabernero, Héctor G. Palmer
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 644–656.
https://doi.org/10.1158/1078-0432.CCR-14-3081
Published: 31 January 2016
View article titled, Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer
Open the PDF for Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer

Celina García-García, Martín A. Rivas, Yasir H. Ibrahim, María Teresa Calvo, Albert Gris-Oliver, Olga Rodríguez, Judit Grueso, Pilar Antón, Marta Guzmán, Claudia Aura, Paolo Nuciforo, Katti Jessen, Guillem Argilés, Rodrigo Dienstmann, Andrea Bertotti, Livio Trusolino, Judit Matito, Ana Vivancos, Irene Chicote, Héctor G. Palmer, Josep Tabernero, Maurizio Scaltriti, José Baselga, Violeta Serra
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (24): 5499–5510.
https://doi.org/10.1158/1078-0432.CCR-14-3091
Published: 14 December 2015
View article titled, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer
Open the PDF for MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by <em>TP53</em> Mutation in Preclinical Models of Colorectal Cancer in another window
Includes: Supplementary data